Drug court utilization of medications for opioid use disorder in high opioid mortality communities

IF 3.7 2区 医学 Q1 PSYCHOLOGY, CLINICAL Journal of Substance Abuse Treatment Pub Date : 2022-10-01 DOI:10.1016/j.jsat.2022.108850
Douglas B. Marlowe , David S. Theiss , Erika M. Ostlie , John Carnevale
{"title":"Drug court utilization of medications for opioid use disorder in high opioid mortality communities","authors":"Douglas B. Marlowe ,&nbsp;David S. Theiss ,&nbsp;Erika M. Ostlie ,&nbsp;John Carnevale","doi":"10.1016/j.jsat.2022.108850","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>A 2012 national survey found low utilization of medication for opioid use disorder (MOUD) in US drug courts. This study provides an update on MOUD policies and practices among drug courts in communities that the opioid epidemic has substantially impacted.</p></div><div><h3>Methods</h3><p>The study surveyed adult drug courts (<em>N</em><span> = 169, 80 % response rate) in US counties with high opioid mortality rates or numbers of opioid-related deaths about their policies and practices relating to MOUD and the overdose-reversal medication, naloxone.</span></p></div><div><h3>Results</h3><p>Nearly three quarters of the programs (73 %) reported providing access to all FDA-approved MOUD medications, &gt;90 % offer agonist medications (buprenorphine and/or methadone), 80 % provide naloxone training, and 62 % distribute naloxone overdose-reversal kits to their clients. Most programs rely principally on medical judgment for medication decisions (75 %), have received staff training on MOUD (65 %), and have arranged for clients to continue receiving agonist medications while serving jail sanctions for program violations (63 %). Nevertheless, only about one quarter to one half of clients with OUDs receive the medications in most programs, and respondents offered few explanations for this disconnect between policy and practice. In addition, 24 % of the programs continue to overrule medication decisions and 36 % of the jails in these communities do not offer agonist medication for drug court clients serving custodial sanctions.</p></div><div><h3>Conclusions</h3><p>Programs have achieved substantial progress in the past decade in improving drug court policies concerning MOUD in communities enduring the worst brunt of the opioid epidemic; however, programs require further guidance to help them understand and rectify service barriers and put intended MOUD policies into effective operation. The authors provide recommendations to enhance MOUD utilization in drug courts and the broader criminal justice system.</p></div>","PeriodicalId":17148,"journal":{"name":"Journal of Substance Abuse Treatment","volume":"141 ","pages":"Article 108850"},"PeriodicalIF":3.7000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Substance Abuse Treatment","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0740547222001325","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction

A 2012 national survey found low utilization of medication for opioid use disorder (MOUD) in US drug courts. This study provides an update on MOUD policies and practices among drug courts in communities that the opioid epidemic has substantially impacted.

Methods

The study surveyed adult drug courts (N = 169, 80 % response rate) in US counties with high opioid mortality rates or numbers of opioid-related deaths about their policies and practices relating to MOUD and the overdose-reversal medication, naloxone.

Results

Nearly three quarters of the programs (73 %) reported providing access to all FDA-approved MOUD medications, >90 % offer agonist medications (buprenorphine and/or methadone), 80 % provide naloxone training, and 62 % distribute naloxone overdose-reversal kits to their clients. Most programs rely principally on medical judgment for medication decisions (75 %), have received staff training on MOUD (65 %), and have arranged for clients to continue receiving agonist medications while serving jail sanctions for program violations (63 %). Nevertheless, only about one quarter to one half of clients with OUDs receive the medications in most programs, and respondents offered few explanations for this disconnect between policy and practice. In addition, 24 % of the programs continue to overrule medication decisions and 36 % of the jails in these communities do not offer agonist medication for drug court clients serving custodial sanctions.

Conclusions

Programs have achieved substantial progress in the past decade in improving drug court policies concerning MOUD in communities enduring the worst brunt of the opioid epidemic; however, programs require further guidance to help them understand and rectify service barriers and put intended MOUD policies into effective operation. The authors provide recommendations to enhance MOUD utilization in drug courts and the broader criminal justice system.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高阿片类药物死亡率社区阿片类药物使用障碍药物的药物法庭使用情况
2012年的一项全国调查发现,美国毒品法庭对阿片类药物使用障碍(mod)的药物使用率很低。这项研究提供了阿片类药物流行受到重大影响的社区中毒品法院的mod政策和做法的最新情况。方法本研究调查了美国阿片类药物死亡率高或阿片类药物相关死亡人数多的县的成人毒品法院(N = 169,有效率80%),了解其与mod和过量逆转药物纳洛酮相关的政策和做法。结果近四分之三(73%)的项目报告提供所有fda批准的mod药物,90%提供激动剂药物(丁丙诺啡和/或美沙酮),80%提供纳洛酮培训,62%向客户分发纳洛酮过量逆转试剂盒。大多数方案主要依靠医学判断来决定用药(75%),对工作人员进行了mod培训(65%),并安排客户在因违反方案而服刑期间继续接受激动剂药物(63%)。然而,在大多数项目中,只有大约四分之一到一半的oud患者接受了药物治疗,受访者对政策与实践之间的这种脱节提供了很少的解释。此外,24%的项目继续否决药物决定,这些社区中36%的监狱不为正在服刑的毒品法庭客户提供激动剂药物。结论:在过去十年中,在阿片类药物流行最严重的社区,在改善毒品法庭有关mod的政策方面,项目取得了实质性进展;然而,这些项目需要进一步的指导,以帮助他们理解和纠正服务障碍,并将预期的国防部政策有效地付诸实施。作者提出了在毒品法庭和更广泛的刑事司法系统中加强mod利用的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.60
自引率
10.30%
发文量
220
期刊介绍: The Journal of Substance Abuse Treatment (JSAT) features original reviews, training and educational articles, special commentary, and especially research articles that are meaningful to the treatment of alcohol, heroin, marijuana, and other drugs of dependence. JSAT is directed toward treatment practitioners from all disciplines (medicine, nursing, social work, psychology, and counseling) in both private and public sectors, including those involved in schools, health centers, community agencies, correctional facilities, and individual practices. The editors emphasize that JSAT articles should address techniques and treatment approaches that can be used directly by contemporary practitioners.
期刊最新文献
Not in my treatment center: Leadership's perception of barriers to MOUD adoption Peer support to reduce readmission in Medicaid-enrolled adults with substance use disorder National trends in buprenorphine prescribing before and during the COVID-19 pandemic A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations An intervention pilot to facilitate harm reduction service decentralization in Vietnam
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1